Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone

Inclusion Criteria

• PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0)
• No lytic lesions on skeletal survey and whole body positron emission tomography (PET)/computed tomography (CT) other than a single lesion associated with solitary bone plasmacytoma
• For patients pre-registering after the completion of radiation therapy, documentation of a bone marrow aspirate and biopsy containing < 10% clonal plasma cells prior to start of radiation therapy
• For patients pre-registering before the start of radiation therapy, documentation of bone marrow aspirate and biopsy containing < 10% clonal plasma cells; radiation therapy should preferably begin within 28 days after bone marrow biopsy
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• All patients are required to be pre-registered to A061402 in order to submit post-radiation therapy (RT) bone marrow aspirate specimens to Roswell Park for occult marrow disease (OMD) detection by flow cytometry; this submission is required prior to registration to confirm eligibility
• REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
• No lytic lesions on skeletal survey and whole body PET/CT other than a single lesion associated with solitary bone plasmacytoma within 28 days prior to registration
• Bone marrow aspirate and biopsy containing < 10% clonal plasma cells performed after completion of RT and within 28 days prior to registration
• Participants must have disease that is detectable after radiation by one of the three measures below: * Elevated serum M protein or * Abnormal serum free light chain (FLC) assay: involved FLC level > upper limits of normal with abnormal serum FLC ratio and/or * >= 50 plasma cells detectable by multicolor flow cytometry, at a sensitive level of 10^-4 (determined by central review)
• No major surgery within 21 days of registration with stabilization or resolution of surgical adverse events
• No investigational agent within 21 days prior to registration
• No ongoing therapy with corticosteroids greater than 10 mg of prednisone or its equivalent per day; please note: inhaled and topical steroids are permitted
• No prior proteasome inhibitor or immune-modulating drug (IMiD) use
• Prior bisphosphonate use is permitted
• For all patients: * Radiation dose should range from 4500 cGy to 6000 cGy * No treatment for this disease following radiation therapy
• Not pregnant and not nursing * Females of childbearing potential (FCBP), defined as a female who 1) has achieved menarche (first menstrual cycle) at some point, or 2) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries), or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months): ** Must have a negative serum or urine pregnancy test with a sensitivity of a least 50 mIU/mL within 10-14 days prior to registration and again within 24 hours of starting lenalidomide ** Must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide ** Must agree to ongoing pregnancy testing * Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy
• ECOG performance status 0-2
• Absolute neutrophil count (ANC) >= 1,500/mm^3 (within 14 days of registration)
• Platelet count >= 75,000/mm^3 (within 14 days of registration)
• Hemoglobin >= 10 g/dL (within 14 days of registration)
• Serum creatinine < 2.0 mg/dL (176.8 umol/liter) (within 14 days of registration)
• Serum calcium =< 11.5 mg/dL (within 14 days of registration)
• Calculated (calc.) creatinine clearance > 50 mL/min (within 14 days of registration)
• Bilirubin =< 1.5 x upper limits of normal (ULN) (within 14 days of registration)
• Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN) (within 14 days of registration)
• If history of prior malignancy, subject should be in complete remission for >= 5 years at the time of registration (with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection)
• Human immunodeficiency (HIV) positive (+) patients are eligible provided they meet the other eligibility criteria and: * Cluster of differentiation (CD)4+ cells are >= 250/mm^3 * There is no history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ cell count * The following antiretroviral agents are not allowed: zidovudine, stavudine, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, combination pills with pharmacologic boosters * Recommended antiretroviral regimens to avoid pharmacokinetic (PK) interactions include strand integrase inhibitors with nucleoside reverse transcriptase inhibitors (for example, dolutegravir given with tenofovir and emtricitabine)
• Patients with hepatitis B virus (HBV) infection are eligible provided they meet the other eligibility criteria and: * There is no evidence of hepatic damage related to HBV infection * They have had consistently suppressed HBV viral load to undetectable levels by polymerase chain reaction (PCR) for a minimum of 12 months
• Patients with hepatitis C virus (HCV) infection are eligible provided they meet the other eligibility criteria and: * They have previously undergone curative therapy and have no evidence of active HCV infection * They have no evidence of liver damage owing to prior HCV infection
• Patients with active HCV infection should be referred for HCV treatment and standard radiotherapy for the plasmacytoma
• =< grade 2 peripheral neuropathy; patients with grade 1 peripheral neuropathy with pain will be excluded
• No cardiac arrhythmias within 182 days of registration
• No congestive heart failure (CHF) within 182 days of registration
• No angina or myocardial infarction within 182 days of registration; in view of potential cardiac risk with lenalidomide, patients with stable angina will be excluded
• Patients cannot be on systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use Ginkgo biloba or St. John’s wort within 14 days of registration
• Corrected QT interval (QTc) < 470 milliseconds (msec) on a 12-lead electrocardiogram (ECG) =< 28 days before registration
• Complete dental exam; complete elimination of dental and periodontal pathology including crowns on teeth susceptible to fracture, extraction of non-restorable or periodontally uncorrectable teeth; creation of an oral environment that the patient can efficiently maintain in a high state of health; and oral hygiene instruction to maintain excellent oral health (within 90 days prior to registration)

Exclusion Criteria

• Known allergy to boron or excipients in the formulation
• Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowing
• Infection requiring systemic antibiotic therapy or other serious infection within 14 days before registration
• Diarrhea >= grade 1, based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) categorization within 14 days of registration
• Life-threatening illness unrelated to cancer
• History of erythema nodosum if characterized by a desquamating rash while taking thalidomide, pomalidomide, or similar drugs